Board Change • May 21
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. Director Magnus Brannstrom was the last director to join the board, commencing their role in 2026. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Ankündigung • Feb 19
Enzymatica AB (publ), Annual General Meeting, May 07, 2026 Enzymatica AB (publ), Annual General Meeting, May 07, 2026, at 14:30 W. Europe Standard Time. Location: lund. Sweden Ankündigung • Dec 13
Enzymatica AB (Publ) Announces CFO Changes Enzymatica AB (publ) announced the appointment of Kristina Rylander as Acting CFO during a transition period in the spring of 2026. She will assume the role on 1 March 2026, following the departure of the current CFO, Therese Filmersson, as previously communicated. Kristina will be responsible for Enzymatica's finance function until Holger Lembrér assumes his position as the new permanent CFO, no later than 13 April 2026. Kristina Rylander has, for an extended period, served as a consultant to Enzymatica, which has provided her with insight into the company's operations and processes. In her role as Acting CFO, she will ensure continuity in Enzymatica's financial reporting, internal processes, and ongoing projects. Ankündigung • Oct 14
Enzymatica Expands the ColdZyme Range with A New Flavor - Eucalyptus Enzymatica expands the ColdZyme range with a new flavour - Eucalyptus. The new flavour offers the same barrier technology and clinically proven benefit against common cold viruses, now with a fresh and cooling taste experience. Like other products in the series, ColdZyme Eucalyptus creates a protective barrier in the throat that helps reduce the viral load, shorten the duration of a cold, and relieve symptoms. The ColdZyme range previously included menthol and strawberry flavours - with Eucalyptus now introduced as a fresh, cooling alternative. The launch of ColdZymeEucalyptus will take place in October in Sweden. The product will be available in pharmacies and online. ColdZyme has been shown in peer-reviewed studies to reduce viral load by up to 94% and shorten the duration of a cold by an average of 40%. Ankündigung • Oct 13
Enzymatica AB (Publ) Appoints Holger Lembrér as CFO, Effective April 2026 Enzymatica AB (publ) has appointed Holger Lembrér as new Chief Financial Officer (CFO). He will assume the position no later than April 2026 and will be part of the company's executive management team. Holger Lembrér brings extensive experience as CFO and finance executive from international and publicly listed companies, primarily within the MedTech, Pharma and industrial sectors. He most recently served as CFO at Boule Diagnostics, where he held overall responsibility for the Group's finance function. Prior to that, Holger was CFO at Oncopeptides and held several senior positions within ASSA ABLOY, including CFO for the Senior Care business area and Investor Relations Officer at Group level. He began his career as an auditor at EY. Ankündigung • Aug 22
Enzymatica AB (Publ) Appoints Claus Egstrand as Member of Board of Directors Enzymatica AB (publ) on 22 August 2025 held an Extraordinary General Meeting approved Claus Egstrand was elected as an ordinary member of the Board of Directors for the period until the end of the next Annual General Meeting. Ankündigung • Aug 13
Enzymatica AB (Publ) Announces Chief Executive Officer Changes The Board of Directors of Enzymatica AB (publ) has appointed Sana Alajmovic as the new Chief Executive Officer. She succeeds Claus Egstrand, who has announced that he is stepping down from his operational role, but he will be proposed to join the company's Board of Directors in order to ensure continuity. Sana Alajmovic is the co-founder and current CEO of Sigrid Therapeutics. She brings extensive experience from business development and leadership within the life science sector, with a strong track record in commercializing research and developing strategic partnerships with international pharmaceutical and consumer health companies. Known for her strategic thinking and dynamic, empathetic leadership, she has established herself as a pioneer in the industry. Sana Alajmovic has received several awards for her entrepreneurship and leadership, including Sweden's Most Important Female Founder by Dagens Industri in 2021 and Female Leader of the Future by Ledarna in both 2020 and 2021. She has also been named one of the world's top life science innovators under the age of 40. Sana Alajmovic will assume her new role no later than 31 January 2026. Ankündigung • Jun 30
Enzymatica AB (Publ) Announces Step Down of Therese Filmersson as CFO Enzymatica AB (publ) announced that the company's Chief Financial Officer (CFO), Therese Filmersson, has decided to leave her position. The decision has been made in mutual agreement between Therese Filmersson and the company's Board of Directors. Therese Filmersson will remain in her role during the notice period to ensure a smooth transition. The recruitment process to find her successor has been initiated. Ankündigung • Jun 21
Enzymatica AB (publ) to Report Fiscal Year 2025 Final Results on Apr 14, 2026 Enzymatica AB (publ) announced that they will report fiscal year 2025 final results on Apr 14, 2026 Ankündigung • Apr 03
Enzymatica AB (publ), Annual General Meeting, May 07, 2025 Enzymatica AB (publ), Annual General Meeting, May 07, 2025, at 14:30 W. Europe Standard Time. Location: elite hotel ideon, scheelevagen 27, lund Sweden Ankündigung • Feb 18
Enzymatica AB (publ) to Report Fiscal Year 2025 Results on Feb 18, 2026 Enzymatica AB (publ) announced that they will report fiscal year 2025 results on Feb 18, 2026 Ankündigung • Jan 09
Enzymatica AB Appoints Anna Söderlund as Senior Director Marketing & Sales Enzymatica AB (publ) announced that Anna Söderlund has joined as the new Senior Director Marketing & Sales. With over 25 years of experience in the Life Science industry, where she has held leading roles at global companies such as Pfizer and MSD, Anna brings solid expertise to the company. Anna Söderlund holds a Master of Science in Economics from Linköping University and has previously successfully worked in key roles in marketing, sales and business development. The recruitment of Anna Söderlund strengthens Enzymatica's commitment to further expand and establish itself as a leading player in its segment. Anna Söderlund has taken up her position and is part of Enzymatica's Group Management. Reported Earnings • Nov 09
Third quarter 2024 earnings released Third quarter 2024 results: Revenue: kr12.6m (down 5.3% from 3Q 2023). Net loss: kr7.25m (loss narrowed 22% from 3Q 2023). Revenue is forecast to grow 65% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 50% per year, which means it is performing significantly worse than earnings. Ankündigung • Aug 17
Enzymatica AB (publ) Announces Final Results from Independent Clinical Study of Coldzyme Show Duration of Illness Lowered by Approximately 5 Days Enzymatica AB announced that the University of Kent has published final results for the Primary Endpoint from the now completed double-blind, placebo-controlled, randomized trial. The study now completed is an independent, investigator initiated in vivo study led by Glen Davison, professor of sports and exercise science and researcher in exercise immunology at the University of Kent, in England. ColdZyme directly forms a physical barrier in the mouth and throat that coats, moisturizes and protects the oral cavity and throat, trapping viruses and inactivating and inhibiting the ability of trapped viruses to infect cells and reproduce. The over-the-counter mouth spray has been certified according to the EU regulation MDR (class III) by Eurofins, an approved European control body for medical devices. The certification entails stricter requirements for the evidence of clinical validity, safe design and market surveillance. ColdZyme products are now MDR certified with the following expanded intended uses: Treat and relieve cold and flu-like symptoms. and with the following extended product claims: Protects against viruses that cause cold and flu-like infections in the upper respiratory tract. Shortens the duration of cold and flu-like infections of the upper respiratory tract if used at an early stage of the infection. Relieves cold and flu-like symptoms, including sore throat. New Risk • Jul 22
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: kr56m Forecast net loss in 2 years: kr16m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr16m net loss in 2 years). Shareholders have been diluted in the past year (5.6% increase in shares outstanding). Revenue is less than US$5m (kr45m revenue, or US$4.2m). Market cap is less than US$100m (€29.9m market cap, or US$32.5m). Breakeven Date Change • Jul 22
No longer forecast to breakeven The 2 analysts covering Enzymatica no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of kr12.3m in 2026. New consensus forecast suggests the company will make a loss of kr46.2m in 2026. Ankündigung • Jul 20
Enzymatica AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 131.770487 million. Enzymatica AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 131.770487 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 69,352,888
Price\Range: SEK 1.9
Transaction Features: Rights Offering Reported Earnings • Jul 19
Second quarter 2024 earnings released: kr0.08 loss per share (vs kr0.07 loss in 2Q 2023) Second quarter 2024 results: kr0.08 loss per share (further deteriorated from kr0.07 loss in 2Q 2023). Revenue: kr6.43m (down 27% from 2Q 2023). Net loss: kr13.8m (loss widened 20% from 2Q 2023). Revenue is forecast to grow 58% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 47% per year, which means it is performing significantly worse than earnings. Recent Insider Transactions • Jun 21
Independent Director recently bought €405k worth of stock On the 13th of June, Gudmundur Palmason bought around 2m shares on-market at roughly €0.26 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €387k more in shares than they have sold in the last 12 months. New Risk • Jun 17
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr36m free cash flow). Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr3.8m net loss in 2 years). Shareholders have been diluted in the past year (5.6% increase in shares outstanding). Revenue is less than US$5m (kr47m revenue, or US$4.5m). Market cap is less than US$100m (€40.7m market cap, or US$43.7m). Ankündigung • Jun 15
Enzymatica AB (Publ) Announces Interim Results from Independent Clinical Study of Coldzyme® Show Duration of Illness Lowered by Approximately 5 Days Enzymatica AB announced that University of Kent has earlier this afternoon published interim results from the ongoing double-blind, placebo-controlled, randomized on the effects of ColdZyme and the product's effect on treating the symptoms and duration of Upper Respiratory Tract Infections (URTI). Interim results have showed that Enzymatica's ColdZyme oral spray reduces the amount of rhinovirus and reduces the number of sick days by approximately five days, with number of sick days being the primary endpoint of the study. The study is an independent, investigator-initiated in vivo study led by Glen Davison, professor of sports and exercise science and researcher in exercise immunology at the University of Kent, in England. Glen Davison researches the effects of training and exercise on the immune system and the body's resistance to infections. The main focus is evaluating products and measures that can help prevent upper respiratory tract infections, such as the common cold. Glen Davison and his research team have been studying the effects of Cold Zyme since 2017 and published the first study four years ago. The study is investigator-initiated, prospective, double-blind, placebo- controlled, and randomized. The study includes roughly 160 athletes in endurance sports, divided into two groups, where one received ColdZyme and the other a placebo. The participants have kept a training diary and filled in a daily questionnaire about symptoms in the upper respiratory tract. When participants experienced symptoms, they took throat samples and began using the mouth spray as instructed. ColdZyme directly forms a physical barrier in the mouth and throat that coats, moisturizes and protects the oral cavity and throat, trapping viruses and inactivating and inhibiting the ability of trapped viruses to infect cells and reproduce. The over-the-counter mouth spray has been certified according to the EU regulation MDR (class III) by Eurofins, an approved European control body for medical devices. The certification entails stricter requirements for the evidence of clinical validity, safe design and market surveillance. ColdZyme products are now MDR certified with the following expanded intended uses: Treat and relieve cold and flu-like symptoms. and with the following extended product claims: Protects against viruses that cause cold and flu-like infections in the upper respiratory tract. Shortens the duration of cold and flu-like infections of the upper respiratory tract if used at an early stage of the infection. Relieves cold and flu-like symptoms, including sore throat. Breakeven Date Change • May 02
Forecast to breakeven in 2026 The 2 analysts covering Enzymatica expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 29% per year to 2025. The company is expected to make a profit of kr12.6m in 2026. Average annual earnings growth of 76% is required to achieve expected profit on schedule. New Risk • Apr 30
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr36m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr36m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr24m net loss in 2 years). Share price has been volatile over the past 3 months (9.4% average weekly change). Shareholders have been diluted in the past year (5.6% increase in shares outstanding). Revenue is less than US$5m (kr47m revenue, or US$4.3m). Market cap is less than US$100m (€42.9m market cap, or US$46.1m). Reported Earnings • Apr 25
First quarter 2024 earnings released: kr0.11 loss per share (vs kr0.091 loss in 1Q 2023) First quarter 2024 results: kr0.11 loss per share (further deteriorated from kr0.091 loss in 1Q 2023). Revenue: kr9.42m (down 28% from 1Q 2023). Net loss: kr18.9m (loss widened 26% from 1Q 2023). Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 35% per year, which means it is performing significantly worse than earnings. New Risk • Apr 08
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (kr15m net loss in 3 years). Share price has been volatile over the past 3 months (8.7% average weekly change). Shareholders have been diluted in the past year (5.6% increase in shares outstanding). Revenue is less than US$5m (kr51m revenue, or US$4.8m). Market cap is less than US$100m (€52.3m market cap, or US$56.7m). Ankündigung • Mar 28
Enzymatica AB (publ) Announces Composition of Nomination Committee Enzymatica AB (publ) announced the nomination committee, in respect of the annual general meeting 2024, has been comprised of Mats Andersson (Abanico Invest AB as well as private holdings), Håkan Roos (Roosgruppen AB), Björn Algkvist (Fibonacci Growth Capital AB), Guðmundur Pálmason (Fortus hf.) and the chairman of the board, Bengt Baron. Björn Algkvist served as chairman of the Nomination Committee. New Risk • Mar 26
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: kr50m Forecast net loss in 3 years: kr15m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (kr15m net loss in 3 years). Share price has been volatile over the past 3 months (8.9% average weekly change). Revenue is less than US$5m (kr51m revenue, or US$4.8m). Market cap is less than US$100m (€43.7m market cap, or US$47.5m). Breakeven Date Change • Mar 26
No longer forecast to breakeven The 2 analysts covering Enzymatica no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of kr22.6m in 2025. New consensus forecast suggests the company will make a loss of kr10.3m in 2025. Ankündigung • Mar 15
Enzymatica AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 27.37614 million. Enzymatica AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 27.37614 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 9,125,380
Price\Range: SEK 3
Transaction Features: Rights Offering Recent Insider Transactions • Mar 03
Independent Director recently sold €81k worth of stock On the 23rd of February, Gudmundur Palmason sold around 300k shares on-market at roughly €0.27 per share. This transaction amounted to 3.7% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €37k more than they bought in the last 12 months. New Risk • Feb 19
New major risk - Revenue and earnings growth Earnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr41m free cash flow). Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Revenue is less than US$5m (kr51m revenue, or US$4.9m). Market cap is less than US$100m (€44.5m market cap, or US$48.0m). Reported Earnings • Feb 18
Full year 2023 earnings released: kr0.30 loss per share (vs kr0.45 loss in FY 2022) Full year 2023 results: kr0.30 loss per share (improved from kr0.45 loss in FY 2022). Revenue: kr50.9m (up 4.0% from FY 2022). Net loss: kr49.7m (loss narrowed 28% from FY 2022). Revenue is forecast to grow 67% p.a. on average during the next 2 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has fallen by 46% per year, which means it is performing significantly worse than earnings. Ankündigung • Feb 16
Enzymatica AB (publ) to Report Fiscal Year 2023 Final Results on Apr 09, 2024 Enzymatica AB (publ) announced that they will report fiscal year 2023 final results at 9:00 AM, Central European Standard Time on Apr 09, 2024 New Risk • Feb 08
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr65m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr65m free cash flow). Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Revenue is less than US$5m (kr52m revenue, or US$4.9m). Market cap is less than US$100m (€49.1m market cap, or US$52.8m). Reported Earnings • Nov 08
Third quarter 2023 earnings released: kr0.056 loss per share (vs kr0.085 loss in 3Q 2022) Third quarter 2023 results: kr0.056 loss per share (improved from kr0.085 loss in 3Q 2022). Revenue: kr13.3m (down 28% from 3Q 2022). Net loss: kr9.24m (loss narrowed 29% from 3Q 2022). Revenue is forecast to grow 65% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings. Breakeven Date Change • Nov 08 The 2 analysts covering Enzymatica previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 56% per year to 2024. The company is expected to make a profit of kr16.1m in 2025.
Ankündigung • Sep 22
Enzymatica AB (publ) Announces Interim Report from Clinical Study: ColdZyme Significantly Reduces Rhinovirus Viral Load and Symptoms of Sore Throat Enzymatica AB (publ) announced that the first results from an ongoing independent clinical study at the University of Kent, UK, show that ColdZyme® significantly reduces the viral load of rhinovirus, the predominant cause of the common cold. Additionally, participants who used ColdZyme experienced significantly less severe sore throat symptoms than those who used placebo. The researchers are assessing the efficacy of ColdZyme mouth spray on upper respiratory tract infection (URTI) parameters, including viral load, in a randomized, double-blind, and placebo-controlled trial, under free-living conditions in endurance athletes (e.g. runners, cyclists, triathletes). The final study is expected to be published in 2024. The interim results have been submitted for presentation at a scientific conference, and are currently under review, hopefully for presentation early in 2024. The trial is investigator initiated, prospective, double-blind, placebo-controlled, and randomized. So far, it comprises 51 endurance athletes divided into two groups, one which received ColdZyme and the other placebo. Participants kept a training log and filled out a daily questionnaire on upper respiratory tract infection symptoms. When participants experienced symptoms, they were instructed to take self-swabs from their throat and start using the mouth spray according to instructions. The trial builds on a previous study in 2020 by the same research team, showing that ColdZyme reduces the duration and symptoms of common cold in endurance athletes. ColdZyme is a prescription free mouth spray that is sold in more than 30 markets on four continents. It is also marketed under brand names such as ViruProtect®, Physiomer®, Bisolviral® and ADerogyl®. Ankündigung • Aug 23
Enzymatica AB (publ) Announces New Study Enzymatica AB (publ) announced new study: ColdZyme breaks the infection cycle, limiting the spread of viruses to more cells. The researchers believe that ColdZyme would have the same effect on other respiratory viruses. ColdZyme mouth spray is sold in more than 30 markets on four continents, also under brand names such as ViruProtect, Bisolviral and ADerogyl. Previous studies have shown how application of ColdZyme before infection blocks viruses from sticking to human cells. The new study shows that ColdZyme also reduces viral load and the virus's ability to spread in cell cultures that were already infected with virus (influenza A, H3N2). The research from the Medical University of Innsbruck shows a more than 99% lower viral load after only three treatments with ColdZyme, compared to infected cells that were treated with salt solution. Reported Earnings • Jul 19
Second quarter 2023 earnings released: kr0.07 loss per share (vs kr0.10 loss in 2Q 2022) Second quarter 2023 results: kr0.07 loss per share (improved from kr0.10 loss in 2Q 2022). Revenue: kr8.76m (down 8.9% from 2Q 2022). Net loss: kr11.5m (loss narrowed 25% from 2Q 2022). Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Pharmaceuticals industry in Germany. Reported Earnings • Apr 30
First quarter 2023 earnings released: kr0.091 loss per share (vs kr0.12 loss in 1Q 2022) First quarter 2023 results: kr0.091 loss per share (improved from kr0.12 loss in 1Q 2022). Revenue: kr13.0m (up 213% from 1Q 2022). Net loss: kr14.9m (loss narrowed 17% from 1Q 2022). Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Recent Insider Transactions • Mar 15
Independent Director recently sold €133k worth of stock On the 9th of March, Gudmundur Palmason sold around 500k shares on-market at roughly €0.27 per share. This transaction amounted to 5.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €107k more than they bought in the last 12 months. Breakeven Date Change • Mar 12
Forecast to breakeven in 2025 The 2 analysts covering Enzymatica expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 56% per year to 2024. The company is expected to make a profit of kr8.01m in 2025. Average annual earnings growth of 82% is required to achieve expected profit on schedule. Ankündigung • Feb 18
Enzymatica AB (publ) to Report Fiscal Year 2023 Results on Feb 16, 2024 Enzymatica AB (publ) announced that they will report fiscal year 2023 results on Feb 16, 2024 Reported Earnings • Feb 18
Full year 2022 earnings released: kr0.45 loss per share (vs kr0.31 loss in FY 2021) Full year 2022 results: kr0.45 loss per share (further deteriorated from kr0.31 loss in FY 2021). Revenue: kr48.9m (down 14% from FY 2021). Net loss: kr68.7m (loss widened 51% from FY 2021). Revenue is forecast to grow 43% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Breakeven Date Change • Nov 18
No longer forecast to breakeven The analyst covering Enzymatica no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of kr10.4m in 2023. New forecast suggests the company will make a loss of kr995.4k in 2024. Reported Earnings • Nov 03
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: kr18.5m (up 20% from 3Q 2021). Net loss: kr13.1m (loss widened 114% from 3Q 2021). Revenue is forecast to grow 43% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Pharmaceuticals industry in Germany. Reported Earnings • Jul 20
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: kr9.62m (up 57% from 2Q 2021). Net loss: kr15.4m (loss narrowed 22% from 2Q 2021). Over the next year, revenue is forecast to grow 188%, compared to a 7.7% growth forecast for the industry in Germany. Ankündigung • Jun 24
Enzymatica AB (publ) Announces New Data from an Ongoing In-Vitro Study Enzymatica AB (publ) announced the New data from an ongoing in-vitro study shows that company's mouth spray ColdZyme blocks the widespread omicron virus from binding to human cells. This indicates ColdZyme could play an important role against many different coronaviruses, including several SARS-CoV-2 variants. Clinical trials will now be accelerated to further investigate the effect in humans. A research group at the Medical University of Innsbruck, Austria, is currently conducting a multi-level study on the barrier technology used in ColdZyme, Enzymatica's mouth spray against upper respiratory tract viruses causing common cold and flu-like symptoms. Results from the first phase of the study now show that ColdZyme blocks the SARS-CoV-2 omicron virus variant from binding to human cells. The researchers tested ColdZyme mouth spray using a 3D model of human tissue that mimics the surface of the human airway. ColdZyme was sprayed onto the tissue model before application of omicron SARS-CoV-2 virus. The data show that pre-treatment with ColdZyme blocks the omicron virus. The efficacy of ColdZyme against SARS-CoV-2 variants has also been demonstrated in previous in-vitro studies: An in-vitro study conducted by the same research group at the University of Innsbruck, using the same tissue model, showed that ColdZyme hinders binding and infection by another SARS-CoV-2 variant (not omicron). Furthermore, a study conducted by Enzymatica using an in-vitro virucidal efficacy suspension test showed that ColdZyme disabled a SARS-CoV-2 variant by more than 98%. ColdZyme is a CE-marked medical device that treats and alleviates common colds. The product is sold in Sweden, UK, and Iceland under the ColdZyme brand and in around 30 markets under other brands. Breakeven Date Change • May 06
Forecast breakeven date moved forward to 2022 The 2 analysts covering Enzymatica previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of kr8.50m in 2022. Earnings growth of 97% is required to achieve expected profit on schedule. Reported Earnings • Apr 29
First quarter 2022 earnings released: kr0.12 loss per share (vs kr0.062 loss in 1Q 2021) First quarter 2022 results: kr0.12 loss per share (down from kr0.062 loss in 1Q 2021). Revenue: kr4.16m (down 76% from 1Q 2021). Net loss: kr18.0m (loss widened 104% from 1Q 2021). Over the next year, revenue is forecast to grow 193%, compared to a 8.0% growth forecast for the industry in Germany. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Louise Nicolin was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Breakeven Date Change • Apr 27
Forecast breakeven date pushed back to 2023 The 2 analysts covering Enzymatica previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 86% to 2022. The company is expected to make a profit of kr12.7m in 2023. Average annual earnings growth of 105% is required to achieve expected profit on schedule. Ankündigung • Apr 06
Enzymatica AB's Mouth Spray to Be Launches in Turkey Enzymatica AB mouth spray against the common cold will be launched in Turkey, following the approval as a medical device in the country. This opens a new market of more than 80 million consumers. Now Enzymatica's mouth spray against the common cold will be launched in Turkey, following the approval as a medical device by TITCK, the Turkish Medicines and Medical Devices Agency. The product will be marketed, sold, and distributed in Turkey by Sanofi Consumer Health Care under one of its own brands. Recent Insider Transactions • Mar 09
Chairman recently bought €161k worth of stock On the 4th of March, Bengt Baron bought around 349k shares on-market at roughly €0.46 per share. This was the largest purchase by an insider in the last 3 months. Bengt has been a buyer over the last 12 months, purchasing a net total of €532k worth in shares. Ankündigung • Mar 05
Enzymatica and Sanofi Launches Mouth Spray in Mexico Enzymatica and Sanofi started their cooperation in October 2020 and has since launched the mouth spray with patented barrier technology in France and Italy under Sanofi's own brands. With the agreement now being expanded to include Mexico, the size of the markets included in the agreement doubles from approx. 130 million to approx. 260 million consumers. The product will be sold under one of Sanofi's own brands in Mexico, where Sanofi is the market leader within several consumer health care categories. The regulatory approval as a medical device by Cofepris (Mexican health authority) took only four months from application to final approval. Breakeven Date Change • Feb 24
Forecast breakeven date pushed back to 2023 The 2 analysts covering Enzymatica previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 54% to 2022. The company is expected to make a profit of kr12.7m in 2023. Average annual earnings growth of 96% is required to achieve expected profit on schedule. Reported Earnings • Feb 18
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: kr0.30 loss per share (down from kr0.093 loss in FY 2020). Revenue: kr57.2m (down 49% from FY 2020). Net loss: kr45.4m (loss widened 243% from FY 2020). Revenue missed analyst estimates by 17%. Over the next year, revenue is forecast to grow 131%, compared to a 7.6% growth forecast for the pharmaceuticals industry in Germany. Recent Insider Transactions • Jan 19
Independent Director recently sold €391k worth of stock On the 17th of January, Gudmundur Palmason sold around 571k shares on-market at roughly €0.68 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought €453k more than they sold in the last 12 months. Buying Opportunity • Jan 19
Now 25% undervalued after recent price drop Over the last 90 days, the stock is down 46%. The fair value is estimated to be kr0.77, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% per annum over the last 3 years. Earnings per share has grown by 39% per annum over the last 3 years. Breakeven Date Change • Dec 15
Forecast breakeven date pushed back to 2023 The 2 analysts covering Enzymatica previously expected the company to break even in 2022. New consensus forecast suggests the company will make a profit of kr18.7m in 2023. Average annual earnings growth of 105% is required to achieve expected profit on schedule. Recent Insider Transactions • Dec 08
Chairman recently bought €141k worth of stock On the 3rd of December, Bengt Baron bought around 163k shares on-market at roughly €0.86 per share. This was the largest purchase by an insider in the last 3 months. Bengt has been a buyer over the last 12 months, purchasing a net total of €371k worth in shares. Breakeven Date Change • Sep 23
Forecast to breakeven in 2022 The 2 analysts covering Enzymatica expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr915.1k in 2022. Average annual earnings growth of 111% is required to achieve expected profit on schedule. Recent Insider Transactions • Jul 22
Director recently bought €457k worth of stock On the 16th of July, Fredrik Lindberg bought around 500k shares on-market at roughly €0.91 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €579k more in shares than they have sold in the last 12 months. Executive Departure • Jul 04
Head of Corporate Communications Carl-Johan Wachtmeister has left the company On the 1st of July, Carl-Johan Wachtmeister's tenure as Head of Corporate Communications ended after 3.8 years in the role. We don't have any record of a personal shareholding under Carl-Johan's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 1.71 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Jul 04
Head of Corporate Communications Carl-Johan Wachtmeister has left the company On the 1st of July, Carl-Johan Wachtmeister's tenure as Head of Corporate Communications ended after 3.8 years in the role. We don't have any record of a personal shareholding under Carl-Johan's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 1.71 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Jul 04
Head of Corporate Communications Carl-Johan Wachtmeister has left the company On the 1st of July, Carl-Johan Wachtmeister's tenure as Head of Corporate Communications ended after 3.8 years in the role. We don't have any record of a personal shareholding under Carl-Johan's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 1.71 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Jul 04
Head of Corporate Communications Carl-Johan Wachtmeister has left the company On the 1st of July, Carl-Johan Wachtmeister's tenure as Head of Corporate Communications ended after 3.8 years in the role. We don't have any record of a personal shareholding under Carl-Johan's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 1.71 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Jul 04
Head of Corporate Communications Carl-Johan Wachtmeister has left the company On the 1st of July, Carl-Johan Wachtmeister's tenure as Head of Corporate Communications ended after 3.8 years in the role. We don't have any record of a personal shareholding under Carl-Johan's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 1.71 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Jul 04
Head of Corporate Communications Carl-Johan Wachtmeister has left the company On the 1st of July, Carl-Johan Wachtmeister's tenure as Head of Corporate Communications ended after 3.8 years in the role. We don't have any record of a personal shareholding under Carl-Johan's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 1.71 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Jul 04
Head of Corporate Communications Carl-Johan Wachtmeister has left the company On the 1st of July, Carl-Johan Wachtmeister's tenure as Head of Corporate Communications ended after 3.8 years in the role. We don't have any record of a personal shareholding under Carl-Johan's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 1.71 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Jul 04
Head of Corporate Communications Carl-Johan Wachtmeister has left the company On the 1st of July, Carl-Johan Wachtmeister's tenure as Head of Corporate Communications ended after 3.8 years in the role. We don't have any record of a personal shareholding under Carl-Johan's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 1.71 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Jul 04
Head of Corporate Communications Carl-Johan Wachtmeister has left the company On the 1st of July, Carl-Johan Wachtmeister's tenure as Head of Corporate Communications ended after 3.8 years in the role. We don't have any record of a personal shareholding under Carl-Johan's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 1.71 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Jul 04
Head of Corporate Communications Carl-Johan Wachtmeister has left the company On the 1st of July, Carl-Johan Wachtmeister's tenure as Head of Corporate Communications ended after 3.8 years in the role. We don't have any record of a personal shareholding under Carl-Johan's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 1.71 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Jul 04
Head of Corporate Communications Carl-Johan Wachtmeister has left the company On the 1st of July, Carl-Johan Wachtmeister's tenure as Head of Corporate Communications ended after 3.8 years in the role. We don't have any record of a personal shareholding under Carl-Johan's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 1.71 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Jul 03
Head of Corporate Communications Carl-Johan Wachtmeister has left the company On the 1st of July, Carl-Johan Wachtmeister's tenure as Head of Corporate Communications ended after 3.8 years in the role. We don't have any record of a personal shareholding under Carl-Johan's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 1.71 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Jul 03
Head of Corporate Communications Carl-Johan Wachtmeister has left the company On the 1st of July, Carl-Johan Wachtmeister's tenure as Head of Corporate Communications ended after 3.8 years in the role. We don't have any record of a personal shareholding under Carl-Johan's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 1.71 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Jul 03
Head of Corporate Communications Carl-Johan Wachtmeister has left the company On the 1st of July, Carl-Johan Wachtmeister's tenure as Head of Corporate Communications ended after 3.8 years in the role. We don't have any record of a personal shareholding under Carl-Johan's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 1.71 years, which is considered inexperienced in the Simply Wall St Risk Model. Breakeven Date Change • May 27
Forecast breakeven pushed back to 2022 The 2 analysts covering Enzymatica previously expected the company to break even in 2021. New consensus forecast suggests the company will make a profit of kr4.99m in 2022. Earnings growth of 104% is required to achieve expected profit on schedule.